In addition to the clinical trials mentioned above, the clinical and preclinical study of new therapeutic radioisotopes (i.e., alpha emitters), new vector molecules targeting PSMA or other targets will point to future breakthroughs in prostate cancer radionuclide therapy. This evidence concerns the gene FOLH1 and prostate cancer.